Is Oruka Therapeutics, Inc. (ORKA) a Buy, Sell, or Hold?
NASDAQ : ORKA
Oruka Therapeutics, Inc.
$96.51 USD
-$1.35 (-1.38%)
- Volume
- 758.75K
- Average Volume
- 1.47M
- Market Capitalization
- $3.61B
- P/E Ratio
- -40.38
- Dividend Yield
- 0.00%
- Price Target
- $155.50
- Year High
- $99.00
- Year Low
- $12.84
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $23.76
Company Overview
NASDAQ
Lawrence Otto Klein
Biotechnology
Healthcare
ORKA
68
US
USD
Liquidity Metrics
0.00
23.76
23.76
2.98
0.00
Sales & Valuation
-$
0.00
10.94
-39.64
-1.65
Profitability
-$2.31
-$105.43M
0.00%
0.00%
-25.99%
-23.04%
P/E Metrics
-40.38
-0.50
-0.50
Analyst Price Target & Rating
$155.50
$200.00
$120.00
2/5
9 Analysts
-37.94%
Financial Health Scores
121.63
1/9
$378.62M
$504.48M
$17.76M
-$116.25M
Key Metrics (TTM)
$3.57B
0.00
-30.71
23.76
-25.99%
-27.31%
-2.18%
-2.52%
-18826 days
Company Executives
| Name | Title |
|---|---|
| Paul T. Quinlan | General Counsel & Secretary |
| Christopher Finch | Senior VP and Head of Business Development & Strategy |
| Laura Sandler | Chief Operating Officer |
| Joana Goncalves | Chief Medical Officer |
| Lawrence Otto Klein | President, Chief Executive Officer & Director |
| Rajiv Panwar | Senior VP and Head of Chemistry, Manufacturing & Controls |
| Arjun Agarwal | Senior Vice President of Finance & Treasurer |
| Alan Lada | VP of IR & Capital Markets |
Poll Results
No votes yet today — be the first to share your view!
About Oruka Therapeutics, Inc. (NASDAQ:ORKA) Stock
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California. ...
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean
2026-06-27 15:28:05
This biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing clinical-stage developments.
2026-06-24 17:24:01
Arjun Agarwal sold 10,290 shares for a transaction value of approximately ~$608,000, based on a weighted average price of $59.07 per share on May 18, 2026. This sale represented 38.5% of Agarwal's direct holdings, reducing direct ownership from 26,696 to 16,406 shares.
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?
2026-06-12 13:01:14
Oruka Therapeutics, Inc. (ORKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2026-06-10 10:56:04
The mean of analysts' price targets for Oruka Therapeutics, Inc. (ORKA) points to an 111.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million
2026-05-31 10:21:54
This clinical-stage biotech focused on antibody therapies for immunological disorders reported a notable insider sale in its latest filing.
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-28 08:00:00
MENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its presentation at the 2026 Jefferies Global Healthcare Conference, taking place in New York, NY from June 2-4, 2026.
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-13 16:03:00
ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally
2026-05-13 15:49:47
This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other immunology indications.
Frequently Asked Questions
-
What is the current Oruka Therapeutics, Inc. (ORKA) stock price?
-
Oruka Therapeutics, Inc.(NASDAQ:ORKA) stock price is $96.51 in the last trading session. During the trading session, ORKA stock reached the peak price of $99 while $12.84 was the lowest point it dropped to. The percentage change in ORKA stock occurred in the recent session was --1.38% while the dollar amount for the price change in ORKA stock was -$1.35.
-
ORKA's industry and sector of operation?
-
The NASDAQ listed ORKA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ORKA?
-
Paul T. Quinlan | General Counsel & Secretary
Christopher Finch | Senior VP and Head of Business Development & Strategy
Laura Sandler | Chief Operating Officer
Joana Goncalves | Chief Medical Officer
Lawrence Otto Klein | President, Chief Executive Officer & Director -
How many employees does ORKA have?
-
Number of ORKA employees currently stands at 68. ORKA operates from 855 Oak Grove Avenue, Menlo Park, CA 94025, US.
-
Link for ORKA official website?
-
Official Website of ORKA is: http://www.orukatx.com
-
How do I contact ORKA?
-
ORKA could be contacted at phone #203-554-7604 and can also be accessed through its website. ORKA operates from 855 Oak Grove Avenue, Menlo Park, CA 94025, US.
-
How many shares of ORKA are traded daily?
-
The average number of ORKA shares traded daily for last 3 months was 1.47M.
-
What is the market cap of ORKA currently?
-
The market value of ORKA currently stands at $3.61B with its latest stock price at $96.51